Samantha R Horn1, Kelsey C Stoltzfus1, Eric J Lehrer2, Laura A Dawson3, Leila Tchelebi1, Niraj J Gusani4, Navesh K Sharma1, Hanbo Chen5, Daniel M Trifiletti6, Nicholas G Zaorsky7. 1. Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA. 2. Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Radiation Oncology, University of Toronto, Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario Canada. 4. Department of Surgery, Penn State College of Medicine, Hershey, PA, USA; Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA. 5. Department of Radiation Oncology, Amsterdam University Medical Centers - Location VUmc, Amsterdam, Netherlands. 6. Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA. 7. Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA; Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA, USA. Electronic address: nzaorsky@pennstatehealth.psu.edu.
Abstract
AIMS: The objectives of this study were to (1) characterize the epidemiology of liver metastases at the time of primary cancer diagnosis (synchronous liver metastases), (2) characterize the incidence trends of synchronous liver metastases from 2010-2015 and (3) assess survival of patients with synchronous liver metastases. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 was queried to obtain cases of patients with liver metastases at the time of primary cancer diagnosis. The primary cancers with an incidence rate of liver metastasis >0.1 are presented in this analysis. RESULTS: Among 2.4 million cancer patients, 5.14 % of cancer patients presented with synchronous liver metastases. The most common primary site was breast cancers for younger women (ages 20-50), and colorectal cancers for younger men. As patients get older, a more heterogenous population of the top cancers with liver metastases emerges including esophageal, stomach, small intestine, melanoma, and bladder cancer in addition to the large proportion of lung, pancreatic, and colorectal cancers. The 1-year survival of all patients with liver metastases was 15.1 %, compared to 24.0 % in those with non-hepatic metastases. Regression analysis showed that the presence of liver metastasis was associated with reduced survival, particularly in patients with cancers of the testis, prostate, breast, and anus, and in those with melanoma. CONCLUSIONS: The most common primary sites for patients with liver metastases varied based on age at diagnosis. Survival for patients with liver metastasis was significantly decreased as compared to patients without liver metastasis.
AIMS: The objectives of this study were to (1) characterize the epidemiology of liver metastases at the time of primary cancer diagnosis (synchronous liver metastases), (2) characterize the incidence trends of synchronous liver metastases from 2010-2015 and (3) assess survival of patients with synchronous liver metastases. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 was queried to obtain cases of patients with liver metastases at the time of primary cancer diagnosis. The primary cancers with an incidence rate of liver metastasis >0.1 are presented in this analysis. RESULTS: Among 2.4 million cancerpatients, 5.14 % of cancerpatients presented with synchronous liver metastases. The most common primary site was breast cancers for younger women (ages 20-50), and colorectal cancers for younger men. As patients get older, a more heterogenous population of the top cancers with liver metastases emerges including esophageal, stomach, small intestine, melanoma, and bladder cancer in addition to the large proportion of lung, pancreatic, and colorectal cancers. The 1-year survival of all patients with liver metastases was 15.1 %, compared to 24.0 % in those with non-hepatic metastases. Regression analysis showed that the presence of liver metastasis was associated with reduced survival, particularly in patients with cancers of the testis, prostate, breast, and anus, and in those with melanoma. CONCLUSIONS: The most common primary sites for patients with liver metastases varied based on age at diagnosis. Survival for patients with liver metastasis was significantly decreased as compared to patients without liver metastasis.
Authors: L Viganò; B Branciforte; V Laurenti; G Costa; F Procopio; M Cimino; D Del Fabbro; L Di Tommaso; G Torzilli Journal: Ann Surg Oncol Date: 2022-06-10 Impact factor: 4.339
Authors: Emily Latacz; Diederik Höppener; Ali Bohlok; Vincent Donckier; Peter M Siegel; Raymond Barnhill; Marco Gerling; Cornelis Verhoef; Peter B Vermeulen; Sophia Leduc; Sébastien Tabariès; Carlos Fernández Moro; Claire Lugassy; Hanna Nyström; Béla Bozóky; Giuseppe Floris; Natalie Geyer; Pnina Brodt; Laura Llado; Laura Van Mileghem; Maxim De Schepper; Ali W Majeed; Anthoula Lazaris; Piet Dirix; Qianni Zhang; Stéphanie K Petrillo; Sophie Vankerckhove; Ines Joye; Yannick Meyer; Alexander Gregorieff; Nuria Ruiz Roig; Fernando Vidal-Vanaclocha; Larsimont Denis; Rui Caetano Oliveira; Peter Metrakos; Dirk J Grünhagen; Iris D Nagtegaal; David G Mollevi; William R Jarnagin; Michael I D'Angelica; Andrew R Reynolds; Michail Doukas; Christine Desmedt; Luc Dirix Journal: Br J Cancer Date: 2022-06-01 Impact factor: 9.075
Authors: Shelby A Labe; Xi Wang; Eric J Lehrer; Amar U Kishan; Daniel E Spratt; Christine Lin; Alicia K Morgans; Lee Ponsky; Jorge A Garcia; Sara Garrett; Ming Wang; Nicholas G Zaorsky Journal: Clin Genitourin Cancer Date: 2022-02-24 Impact factor: 3.121
Authors: Nicholas G Zaorsky; Menglu Liang; Rutu Patel; Christine Lin; Leila T Tchelebi; Kristina B Newport; Edward J Fox; Ming Wang Journal: Radiother Oncol Date: 2021-02-19 Impact factor: 6.901
Authors: Raghav Chandra; John D Karalis; Charles Liu; Gilbert Z Murimwa; Josiah Voth Park; Christopher A Heid; Scott I Reznik; Emina Huang; John D Minna; Rolf A Brekken Journal: Cancers (Basel) Date: 2021-12-09 Impact factor: 6.639